Abstract:

Objective To study the effect of ginkgolide meglumine combined with batroxobin on serum NSE, high-sensitivity C-reactive protein(hs-CRP) and quality-of-life in patients with acute cerebral infarction(ACI). Methods Totally 108 ACI inpatients were randomly divided into two groups. On the basis of routine treatment, 54 cases in control group were injected with batroxobin, and 54 cases in observation group with ginkgolide meglumine combined with batroxobin. After 14 days of treatment. The clinical efficacy, 1-week, 1-month, and 3-month Barthel index, serum of neuron-specific enolase(NSE) and hs-CRP in two groups were observed. The evaluations were performed in modified Rankin Scale(mRS) scores on the 7th, 15th, 30th and 60th day of treatment, and the incidence of adverse reactions during this period. Results The total effective rate was significantly higher in observation group than in control group (92.15% vs 74.07%, P<0.05). After treatment, Barthel score in observation group was significantly higher than that before treatment, and the score was higher than in control group(P<0.05). The NSE and hs-CRP were significantly lower in observation group than before treatment(P<0.05). mRS score was significantly lower in observation group as compared with control group(P<0.05). There was no significant difference in the incidence of adverse reactions between groups (P>0.05). Conclusion For ACI patients, Ginkgolide meglumine combined with batroxobin has good curative effect, which can significantly improve their activity function, dysfunction, quality-of-life, prognosis, and has high safety.

Key words: cerebral infarction, ginkgolide meglumine, batroxobin